While limited studies exist on the role of Parvibacter in kidney disease, one study revealed that it may prevent peritoneal fibrosis induced by peritoneal dialysis in end-stage kidney disease by enhancing butyrate production, activating PPARγ and inhibiting NF-κB-mediated inflammatory pathways (Wu et al., 2023). Here, PPARG is linked to kidney disorder.